Skip to main content
European Commission logo print header

CLinical impact through AI-assisted MS care

Project description

Precision medicine for multiple sclerosis

Multiple sclerosis (MS) is a chronic inflammatory disorder of the central nervous system associated with myelin destruction and neuroaxonal damage. As neurons gradually lose their ability to transmit signals, patients experience a variety of symptoms and comorbidities with debilitating impact. This heterogeneous nature of MS indicates that a one-size-fits-all management and treatment approach is not appropriate. Funded by the Horizon Europe programme, the CLAIMS project aims to make precision medicine a reality for MS patients. The consortium will create a diagnostic platform that provides a comprehensive and holistic view of the patient’s health status through advanced diagnostic technologies. The goal is to predict disease progression on an individual basis under different treatments and to improve patient outcomes.


Multiple sclerosis (MS) is a devastating immune-mediated disorder of the central nervous system. Since there is no cure available yet for MS, the primary therapeutic goal for MS patients is to slow down disability progression and to reduce relapses at early stages of the disease. Despite 19 available disease modifying treatments (DMTs), the large heterogeneity of the disease, further complicated by the high prevalance of comorbidities and multipharmacy, and the limited understanding of the working mechanisms DMT thereon results in a poor and variable treatment response in a real-world setting. The CLAIMS project is a public-private partnership aiming to address this and make precision medicine for MS patients a reality through data-driven prognosis and treatment advice, in order to better slow down disease progression and eventually conversion to progressive MS. We will develop, validate and submit for regulatory approval a companion diagnostic platform, which offers the MS care team a holistic view of the patient through the visualization of the clinical and subclinical biomarkers and the prediction of the expected disease trajectory under different treatments. For biomarker extraction and treatment prediction, state-of-the-art technologies that allow a reliable and scalable implementation across the world will be used. We believe this platform will initiate the paradigm shift from a trial-and-error, experienced-based treatment of MS patients to a first-time-right, value-based holistic treatment management, and will, hence, improve patient outcomes at a lower total cost of care, enhance patient experience and improve the well-being of the care team.



Net EU contribution
€ 1 375 625,00
Chariteplatz 1
10117 Berlin

See on map

Berlin Berlin Berlin
Activity type
Higher or Secondary Education Establishments
Other funding
€ 500 000,00

Participants (14)